Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.10.19
Views: 500

Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands

Prof Ronald de Wit speaks to ecancer at ESMO 2019 in Barcelona about the CARD study.

He outlines the background and study design, and the premise for this particular design.

Prof de Wit explains the positive results, and also the robust nature of the data. He believes that cabazitaxel will be practise changing, and is well tolerated.

Related videos


no rating
Epidemiology of cancer in India

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation